Enhanced rapamycin delivery to hemangiomas by lipid polymer nanoparticles coupled with anti-VEGFR antibody

Li,Haitao; Teng,Yunfei; Xu,Xia; Liu,Jianyong

doi:10.3892/ijmm.2018.3518

Enhanced rapamycin delivery to hemangiomas by lipid polymer nanoparticles coupled with anti-VEGFR antibody

Authors:
- Haitao Li
- Yunfei Teng
- Xia Xu
- Jianyong Liu
View Affiliations

Affiliations: Department of Vascular Surgery, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China, Department of Pathology, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Published online on: February 28, 2018 https://doi.org/10.3892/ijmm.2018.3518
Pages: 3586-3596

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The most common tumors in children are infantile hemangiomas which could cause morbidity and severe complications. The development of novel alternative drugs to treat infantile hemangiomas is necessary, since Hemangeol is the only US Food and Drug Administration-approved drug for infantile hemangiomas. However, Hemangeol has several disadvantages, including a high frequency of administration and adverse effects. Rapamycin is a well‑established antiangiogenic drug, and we have previously developed rapamycin lipid polymer nanoparticles (R‑PLNPs) as a local sustained‑release drug delivery system to achieve controlled rapamycin release and to decrease the frequency of administration and side effects of rapamycin. To improve the targeting of R‑PLNPs to infantile hemangiomas in the present study, R‑PLNPs were modified to include an antibody against vascular endothelial growth factor receptor (VEGF). The characteristics, and the anti‑hemangioma activity of the resulting R‑PLNPs coupled with the anti‑VEGFR2 antibody (named R‑PLNPs‑V) were examined in vitro and in vivo. R‑PLNPs‑V possessed a small size (115 nm) and sustained drug release for 6 days. The anti‑VEGFR2 antibody promoted the targeting and cytotoxic effect of R‑PLNPs‑V to human hemangioma endothelial cells and human umbilical vein endothelial cells. Using a subcutaneous infantile hemangioma xenograft in mice, the in vivo therapeutic effect (evaluated with hemangioma weight, volume, and microvessel density) of R‑PLNPs‑V was demonstrated to be superior compared with rapamycin alone and other non‑targeted nanoparticles, without any total body weight loss. In summary, R‑PLNPs‑V could facilitate targeted delivery and sustained release of rapamycin to infantile hemangiomas, and thus may represent a promising candidate treatment for infantile hemangiomas.

View Figures

View References

1	Kilcline C and Frieden IJ: Infantile hemangiomas: How common are they? A systematic review of the medical literature. Pediatr Dermatol. 25:168–173. 2008. View Article : Google Scholar : PubMed/NCBI
2	Chang LC, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, Horii KA, Lucky AW, Mancini AJ, Metry DW, et al: Growth characteristics of infantile hemangiomas: Implications for management. Pediatrics. 122:360–367. 2008. View Article : Google Scholar : PubMed/NCBI
3	Chen TS, Eichenfield LF and Friedlander SF: Infantile hemangiomas: An update on pathogenesis and therapy. Pediatrics. 131:99–108. 2013. View Article : Google Scholar
4	Sethuraman G, Yenamandra VK and Gupta V: Management of infantile hemangiomas: Current trends. J Cutan Aesthet Surg. 7:75–85. 2014. View Article : Google Scholar : PubMed/NCBI
5	Léaute-Labrèze C, Boccara O, Degrugillier-Chopinet C, Mazereeuw-Hautier J, Prey S, Lebbé G, Gautier S, Ortis V, Lafon M, Montagne A, et al: Safety of oral rapamycin for the treatment of infantile hemangioma: A Systematic Review. Pediatrics. 138:pii: e20160353. 2016. View Article : Google Scholar
6	Kaur A and Sharma S: Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases. Inflammopharmacology. 25:293–312. 2017. View Article : Google Scholar : PubMed/NCBI
7	Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G and Milella M: Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 66:5549–5554. 2006. View Article : Google Scholar : PubMed/NCBI
8	Medici D and Olsen BR: Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF. PLoS One. 7:e429132012. View Article : Google Scholar : PubMed/NCBI
9	Zheng N, Ding X and Jahan R: Low concentration of rapamycin inhibits hemangioma endothelial cell proliferation, migration, and vascular tumor formation in mice. Curr Ther Res Clin Exp. 76:99–103. 2014. View Article : Google Scholar : PubMed/NCBI
10	Johnson RW: Sirolimus (Rapamune) in renal transplantation. Curr Opin Nephrol Hypertens. 11:603–607. 2002. View Article : Google Scholar : PubMed/NCBI
11	Stallone G, Infante B, Grandaliano G and Gesualdo L: Management of side effects of sirolimus therapy. Transplantation. 87(8 Suppl): S23–S26. 2009. View Article : Google Scholar : PubMed/NCBI
12	Almeida H, Amaral MH, Lobao P, Frigerio C and Sousa Lobo JM: Nanoparticles in ocular drug delivery systems for topical administration: Promises and challenges. Curr Pharm Des. 21:5212–5224. 2015. View Article : Google Scholar : PubMed/NCBI
13	Li H, Teng Y, Sun J and Liu J: Inhibition of hemangioma growth using lipid polymer nanoparticles for delivery of rapamycin. Biomed Pharmacother. 95:875–884. 2017. View Article : Google Scholar : PubMed/NCBI
14	Gao J, Chen H, Song H, Su X, Niu F, Li W, Li B, Dai J, Wang H and Guo Y: Antibody-targeted immunoliposomes for cancer treatment. Mini Rev Med Chem. 13:2026–2035. 2013. View Article : Google Scholar : PubMed/NCBI
15	Gao J, Feng SS and Guo Y: Antibody engineering promotes nanomedicine for cancer treatment. Nanomedicine (Lond). 5:1141–1145. 2010. View Article : Google Scholar
16	Li W, Li J, Gao J, Li B, Xia Y, Meng Y, Yu Y, Chen H, Dai J, Wang H and Guo Y: The fine-tuning of thermosensitive and degradable polymer micelles for enhancing intracellular uptake and drug release in tumors. Biomaterials. 32:3832–3844. 2011. View Article : Google Scholar : PubMed/NCBI
17	Eskens FA and Verweij J: The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer. 42:3127–3139. 2006. View Article : Google Scholar : PubMed/NCBI
18	Tugues S, Koch S, Gualandi L, Li X and Claesson-Welsh L: Vascular endothelial growth factors and receptors: Antiangiogenic therapy in the treatment of cancer. Mol Aspects Med. 32:88–111. 2011. View Article : Google Scholar : PubMed/NCBI
19	Wang Z, Li J, Xu X, Duan X and Cao G: Urea immunoliposome inhibits human vascular endothelial cell proliferation for hemangioma treatment. World J Surg Oncol. 11:3002013. View Article : Google Scholar : PubMed/NCBI
20	Humar R, Kiefer FN, Berns H, Resink TJ and Battegay EJ: Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J. 16:771–780. 2002. View Article : Google Scholar : PubMed/NCBI
21	Nyström AM and Fadeel B: Safety assessment of nanomaterials: Implications for nanomedicine. J Control Release. 161:403–408. 2012. View Article : Google Scholar : PubMed/NCBI
22	Nelson AL, Dhimolea E and Reichert JM: Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 9:767–774. 2010. View Article : Google Scholar : PubMed/NCBI
23	Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, et al: Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clin Cancer Res. 8:1172–1181. 2002.PubMed/NCBI